VivoSeq
Other

AIDS

27

Pipeline Programs↗

2

Active Trials↗

19

Companies Involved↗

AIDS is an emerging landscape with 27 programs across 19 companies. The most active players are Iovance Biotherapeutics, Inc., Merck & Co., Gilead. 18 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

0/100

Mech. Concentration

29/100

Completion Rate

95/100

Attrition Rate

4/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

I

Iovance Biotherapeutics, Inc.

1 program

Phase 1Merck & Co. logo

Merck & Co.

1 program

Phase 3Gilead logo

Gilead

3 programs

ApprovedAbbVie logo

AbbVie

1 program

ApprovedA

Auxilium

1 program

ApprovedM

Milestone Pharmaceuticals Inc.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

93%

Small molecule

26 of 28 classified programs — the dominant modality here.

7%ALL OTHERSProtein / enzyme14%Peptide14%

Small molecule leads; the ring shows all 28 classified programs, each share of the total. Modality classified for 100% of 29 pipeline programs.

Analysis

Trial Status

24

clinical trials

Completed20 · 83%
Recruiting2 · 8%
Terminated1 · 4%
Unknown status1 · 4%

Clinical Trials

Trial Activity

24 trials

NSAIDs Stent Study
Recruiting·WWashington University School of Medicine·Phase 1·NCT03638999·36 enrolled
Microvascular Angina Intervention With Compound Danshen Dripping Pill (MAIDS)
Recruiting·QQilu Hospital of Shandong University·Phase 4·NCT06092736·100 enrolled
Maraviroc and NeuroAIDS Pathogenesis
Completed·UUniversity of Hawaii·Phase 2/3·NCT02159027·48 enrolled
Evaluation of the Epidermal Langerhans Cell Population in AIDS / ARC Patients by the Topical Application of a Potent Contact Allergen (1-Chloro-2,4-Dinitro-Chlorobenzene) (DNCB)
Completed·UUniversity of California, San Francisco·N/A·NCT00002031
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 2·NCT01928927·58 enrolled
A Study of DTC in Patients With AIDS and AIDS Related Complex
Completed·MMerieux Institute·N/A·NCT00002069
A Study of BMY-27857 in Patients With AIDS or AIDS Related Complex
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000988·40 enrolled
A Study of Isoprinosine in Patients With Severe AIDS
Completed·NNewport Pharmaceuticals International·N/A·NCT00002295
The Effects of Anti-HIV Drugs in HIV-Infected Patients Who Do Not Have AIDS
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00001024·32 enrolled
A Study of Dextran Sulfate in HIV-Infected Patients and in Patients With AIDS or AIDS Related Complex (ARC)
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001009·60 enrolled
A Study of Lobucavir in Patients With AIDS
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·N/A·NCT00002352·30 enrolled
Nutrition Intervention in AIDS Wasting
Completed·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 4·NCT00006167
A Study of ddI in Patients With AIDS Who Become Sicker While Taking Zidovudine
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·N/A·NCT00002274
PGE2 Levels in Patient Treated With NSAIDs
Completed·UUniversity of Trieste·Phase 3·NCT03597867·104 enrolled
A Phase I Study of Recombinant CD4(rCD4) in Patients With AIDS and AIDS-Related Complex
Completed·Roche logoRoche·N/A·NCT00002005
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)